Trial Profile
A Phase II, Multicenter, Open-label, Randomized Two-year Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jun 2023
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Haemochromatosis; Iron overload
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 17 May 2023 Status changed from active, no longer recruiting to completed.
- 17 Apr 2023 Planned End Date changed from 18 Apr 2023 to 24 Apr 2023.
- 10 Mar 2022 This trial has been completed in Slovakia according to European Clinical Trials Database record